Skip to main content

STERIS Value Stock - Dividend - Research Selection

Steris

ISIN: IE00BFY8C754 , WKN: A2PGLV

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


STERIS Q3 Earnings Call Highlights

2026-02-07
STERIS (NYSE:STE) executives highlighted broad-based third-quarter fiscal 2026 growth, improved earnings, and ongoing tariff headwinds during the company’s earnings call, while maintaining full-year guidance and pointing to a more challenging comparison in the fourth quarter. Third-quarter results:

Dividend Champion, Contender, And Challenger Highlights: Week Of February 8

2026-02-06
Get this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates. Read the full analysis here.

STERIS: A Bump In The Road For A Reliable Name

2026-02-06
STERIS plc is rated a Buy, offers a resilient, high-quality business model with some premium valuation. Learn more about STE stock here.

Steris PLC (STE) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Tariff Challenges

2026-02-05
Steris PLC (STE) reports a 9% revenue increase and robust free cash flow, while navigating tariff impacts and maintaining fiscal 2026 outlook.

STERIS (STE) Q3 2026 Earnings Call Transcript

2026-02-05
Karen Burton: And I do have a few words to caution before we open for comments. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in STERIS' securities filings.

STE Q3 Earnings Meet, Revenues Beat, Stock Dips in Aftermarket Trading

2026-02-05
STERIS shares slide after hours as Q3 earnings meet estimates and revenues beat, with investors focused on gross margin contraction despite solid growth.

Stocks making the biggest moves midday: Amazon, Canada Goose, Estee Lauder, Qualcomm & more

2026-02-05
Here are some of the stocks posting the biggest moves in midday trading.

STERIS plc (STE) Q3 2026 Earnings Call Transcript

2026-02-05

Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics

2026-02-04
The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Steris (STE) Meets Q3 Earnings Estimates

2026-02-04
Steris (STE) delivered earnings and revenue surprises of -0.10% and +1.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?